Results 31 to 40 of about 7,679 (193)

Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses

Respiratory Research, 2023
Introduction Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab.
Ayobami Akenroye, Tanawin Nopsopon, Laura Cho, Matthew Moll, Scott T. Weiss   +4 more
doaj   +1 more source

Characteristics of new adult users of mepolizumab with asthma in the USA

BMJ Open Respiratory Research, 2021
Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ...
Pamela M McMahon, Ann Chen Wu, Emily Welch, Cheryl N McMahill-Walraven, Aziza Jamal-Allial, Mia Gallagher, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S Brown, Melissa K Van Dyke   +11 more
doaj   +1 more source

May mepolizumab used in asthma correct subfertility? [PDF]

, 2021
İntroduction Asthma is one of the most common chronic airway disease among reproductive period of women. Chronic inflammation in asthma, eosinophilia, high steroid treatment and uncontrolled asthma may cause infertility by affecting the reproductive ...
Guzin Ozden, Pelin Pınar Deniz
core   +1 more source

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Heliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi, Masamitsu Eitoku, Akihito Yokoyama   +2 more
doaj   +1 more source

Comorbidities modify the phenotype but not the treatment effectiveness to mepolizumab in severe eosinophilic asthma [PDF]

, 2023
Background: Comorbidities in severe asthma are common and contribute to disease burden. The severe asthma phenotype and treatment response can be impacted by comorbid conditions.
Bowler, S., Gillman, A., Reddel, H. K., Grainge, C., Chien, J., McDonald, V. M., Stevens, S., Bowden, J. J., Rimmer, J., Lee, J., Katelaris, Constance H. (R12307), Farah, C. S., Hew, M., Harvey, E. S., Chung, L. P., Wark, P. A., Harkness, N., Katsoulotos, G. P., Baraket, M., Australian Mepolizumab Registry Investigators, Radhakrishna, N., Upham, J. W., Reynolds, P. N., Kritikos, V., Bardin, P., Sivakumaran, P., Harrington, Z., Jenkins, C., Gibson, P. G., Langton, D., Thomas, D., Peters, M.   +31 more
core   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source

Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

Respiratory Medicine Case Reports, 2023
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to ...
Stylianos K. Vittorakis, Georgia Giannakopoulou, Konstantinos Samitas, Eleftherios Zervas   +3 more
doaj   +1 more source

Efficacy of mepolizumab in usual clinical practice and characteristics of responders : Mepolizumab in usual clinical practice [PDF]

, 2021
Background: Severe eosinophilic asthma is a high-burden disease. Mepolizumab has been effective in several randomized clinical trials. However, such success might not be applicable to patients treated in usual clinical practice.
Dacal-Quintas, Raquel, Juan José Nieto-Fontarigo, Uxío Calvo-Alvarez, Blanco-Cid, Nagore, Tamara Lourido-Cebreiro, Blanco-Cid, Nagore,, Nieto-Fontarigo, Juan José,, Corbacho-Abelaira, María Dolores,, Carlos Crespo-Diz, Pallares-Sanmartin, Abel, Gonzalez-Fernandez, Coral,, Nieto-Fontarigo, Juan José, María Dolores Corbacho-Abelaira, Luis Miguel Dominguez-Juncal, Nagore Blanco-Cid, Lourido-Cebreiro, Tamara, Crespo-Diz, Carlos, Luis Perez-De-Llano, Gonzalez-Barcala, Francisco Javier,, Marina Blanco-Aparicio, Mosteiro-Añon, Mar, David Dacal-Rivas, Blanco-Aparicio, Marina, Lund University., Rodríguez-García, Carlota, Gonzalez-Barcala, Francisco Javier, Dominguez-Juncal, Luis Miguel, Calvo-Alvarez, Uxío,, Calvo-Alvarez, Uxío, Perez-De-Llano, Luis, Crespo-Diz, Carlos,, Carlota Rodríguez-García, Abel Pallares-Sanmartin, Raquel Dacal-Quintas, Mar Mosteiro-Añon, Rodríguez-García, Carlota,, Mosteiro-Añon, Mar,, Dominguez-Juncal, Luis Miguel,, Francisco Javier Gonzalez-Barcala, Coral Gonzalez-Fernandez, Lourido-Cebreiro, Tamara,, Dacal-Quintas, Raquel,, Pallares-Sanmartin, Abel,, Dacal-Rivas, David,, Corbacho-Abelaira, María Dolores, Perez-De-Llano, Luis,, Dacal-Rivas, David, Gonzalez-Fernandez, Coral, Blanco-Aparicio, Marina,   +48 more
core   +1 more source